

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kyle J. Lindstrom *et al.*
Serial No.: 10/595,103
Confirmation No.: 2609
Filed: February 14, 2006
For: ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED
IMIDAZOQUINOLINES
Examiner: Niloofar Rahmani
Art Unit: 1625

Certificate of Electronic Filing Under 37 CFR § 1.8

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: March 30, 2010

/Sara J. L. Douglas/
Sara J. L. Douglas

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. § 1.97

This Information Disclosure Statement is being filed with a Request for Continued Examination under 37 C.F.R. § 1.114. Therefore, no fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant would also like to bring to the Examiner's attention the enclosed search reports from a corresponding or related international or foreign patent application:

Serial No.	Date of Mailing	Type(s) of Communication	Docket No.
PCT/US2004/032616	April 18, 2005	International Search Report and Written Opinion	C1271.70017WO00
PCT/US2004/032616	April 13, 2006	International Preliminary Report on Patentability	C1271.70017WO00
PCT/US2004/028021	February 3, 2005	International Search Report and Written Opinion	C1271.70021WO00
PCT/US2004/028021	February 27, 2006	International Preliminary Report on Patentability	C1271.70021WO00

The Applicant would also like to bring to the Examiner's attention the following other information:

Office Communication mailed July 28, 2009 for Application No. 10/595,230 (C1271.70017US01)
Office Communication mailed December 30, 2009 for Application No. 10/595,230 (C1271.70017US01)

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By: /C. Hunter Baker/
C. Hunter Baker, M.D., Ph.D.
Reg. No. 46,533
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1271.70021US02
Date: March 30, 2010
xNDDx